Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Maria Hattinger

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|November 18, 2016
Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcomaMassimo Serra, Claudia Maria Hattinger
Expert Opinion on Drug Metabolism & Toxicology|June 23, 2015
Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcomaClaudia Maria Hattinger, Massimo Serra
International Journal of Molecular Sciences|July 8, 2020
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical ImpactClaudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, et al.
Expert Opinion on Emerging Drugs|August 10, 2010
Emerging drugs for high-grade osteosarcomaClaudia Maria Hattinger, Michela Pasello, Stefano Ferrari, et al.
Cells|April 17, 2020
Genomics and Therapeutic Vulnerabilities of Primary Bone TumorsKatia Scotlandi, Claudia Maria Hattinger, Evelin Pellegrini, et al.
Expert Opinion on Emerging Drugs|August 13, 2019
An update on emerging drugs in osteosarcoma: towards tailored therapies?Claudia Maria Hattinger, Maria Pia Patrizio, Federica Magagnoli, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 21, 2016
Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcomaClaudia Maria Hattinger, Elisa Tavanti, Marilù Fanelli, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 2, 2019
Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatmentClaudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, et al.
Cancers|July 2, 2021
Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment StrategiesClaudia Maria Hattinger, Maria Pia Patrizio, Leonardo Fantoni, et al.
Expert Opinion on Emerging Drugs|May 30, 2015
Advances in emerging drugs for osteosarcomaClaudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Metabolism & Toxicology|November 18, 2016
Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcomaMassimo Serra, Claudia Maria Hattinger
Expert Opinion on Drug Metabolism & Toxicology|June 23, 2015
Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcomaClaudia Maria Hattinger, Massimo Serra
International Journal of Molecular Sciences|July 8, 2020
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical ImpactClaudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, et al.
Expert Opinion on Emerging Drugs|August 10, 2010
Emerging drugs for high-grade osteosarcomaClaudia Maria Hattinger, Michela Pasello, Stefano Ferrari, et al.
Cells|April 17, 2020
Genomics and Therapeutic Vulnerabilities of Primary Bone TumorsKatia Scotlandi, Claudia Maria Hattinger, Evelin Pellegrini, et al.
Expert Opinion on Emerging Drugs|August 13, 2019
An update on emerging drugs in osteosarcoma: towards tailored therapies?Claudia Maria Hattinger, Maria Pia Patrizio, Federica Magagnoli, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 21, 2016
Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcomaClaudia Maria Hattinger, Elisa Tavanti, Marilù Fanelli, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 2, 2019
Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatmentClaudia Maria Hattinger, Maria Pia Patrizio, Silvia Luppi, et al.
Cancers|July 2, 2021
Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment StrategiesClaudia Maria Hattinger, Maria Pia Patrizio, Leonardo Fantoni, et al.
Expert Opinion on Emerging Drugs|May 30, 2015
Advances in emerging drugs for osteosarcomaClaudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, et al.
Pageof 4